|
[1]
|
Hiari, N. and Rudd, J.H.F. (2011) FDG-PET imaging and cardiovascular inflammation. Current Cardiology Reports, 13, 43-48.
|
|
[2]
|
Rogers, I.S. and Tawakol, A. (2011) Imaging of coronary inflammation with FDG-PET: Feasibility and clinical hurdles. Current Cardiology Reports.
|
|
[3]
|
Matsunari, I., Taki, J., Nakajima, K., Tonami, N. and Hisada, K. (2003) Myocardial viability assessment using nuclear imaging. Annals of Nuclear Medicine, 17, 169 179.
|
|
[4]
|
Barakat, K., Clark, R. and Davi, M. (2004) Valsartan hypertension and cardiovascular disease book. CSF Medical Communications, Witney.
|
|
[5]
|
Aronson, J.K. (2009) Meyler’s side effects of cardiovascular drugs book. Elsevier Science, Amsterdam.
|
|
[6]
|
Holwerda, N.J., Fogari, R., Angeli, P., Porcellati, C., Hereng, C. and Oddou-Stock, P. (1996) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared with placebo and enalapril. Journal of Hypertension, 14, 1147-1151.
doi:10.1097/00004872-199609000-00016
|
|
[7]
|
Black, H.R., Graff, A., Shute, D., Stoltz, R., Ruff, D. and Levine, J. (1997) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension, 11, 483-489. doi:10.1038/sj.jhh.1000482
|
|
[8]
|
Waldmeier, F., Flesch, G., Müller, P., Winkler, T., Kriemler, H.P., Bühlmayer, P. and De Gasparo, M. (1997) Phar macokinetics, disposition and biotransformation of [14C] radiolabeled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 27, 59-71.
|
|
[9]
|
Hermanson, G.T. (2008) Bioconjugated techniques book. 2nd Edition, Elsevier, Amsterdam.
|
|
[10]
|
El-Azony, K.M., El-Mohty, A.A., Killa, H.M., Seddik, U. and Khater, S.I. (2008) An investigation of the 125I-radio iodination of colchicine for medical purposes. Journal of Labelled Compounds and Radiopharmaceuticals, 52, 1.
doi:10.1002/jlcr.1556
|
|
[11]
|
Attallah, K.M. (2002) Pharmaceutical formulation, radio chemical and biological evaluation of some iodine-125 labeled cytotoxic compounds as possible radiotherapeutic agents. M.Sc. Thesis, Zagazig University.
|
|
[12]
|
Rhodes, B.A. (1974) Technetium-99m labeled polypeptides for imaging. Seminars in Nuclear Medicine, 4, 281.
doi:10.1016/S0001-2998(74)80015-2
|
|
[13]
|
Knust, E.J., Dutschka, K. and Machulla, H.J. (1990) Ra diopharmaceutical preparation of 3-123I-α-methyltyrosine for nuclearmedical applications. Journal of Radioanalytical and Nuclear Chemistry, 10, 144
|
|
[14]
|
EL-Ghany, E.A., Moustafa, D. and Shokry, M.S. (2009) Iodine-125-Tamoxifan (125ITX); radioligand for visualization of estrogen receptors: Preparation and tissue distribu tion. Arab Journal of Nuclear Sciences and Applications, 42, 80.
|
|
[15]
|
El-Azony, K.M. (2010) Preparation of 125I-celecoxib with high purity as a possible tumor agent. Journal of Radioanalytical and Nuclear Chemistry, 285, 315-320.
|